Filing Details

06/01/2020 Securities and Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: Schedule 13G Progenics Pharmaceuticals, Inc. As of 03/31/2020 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G/A for the above named company showing beneficial ownership of 5% or more as of 03/31/2020 filed on behalf of Eagle Asset Management, Inc. Very truly yours, Damian Sousa Vice President Chief Compliance Officer DS:CC Enclosures cc: Office of the Corporate Secretary Progenics Pharmaceuticals, Inc. One World Trade Center, 47th Floor New York, NY 10007SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 743187106 (CUSIP Number) Check the following box if a fee is being paid with this statement _____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 743187106 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Eagle Asset Management, Inc. 59-2385219 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) ______ (B) ______ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION State of Florida NUMBER OF 5 SOLE VOTING POWER SHARES 0 BENEFICIALLY 6 SHARED VOTING POWER OWNED - - - AS OF 03/31/20 7 SOLE DISPOSITIVE POWER BY EACH 0 REPORTING 8 SHARED DISPOSITIVE POWER PERSON WITH - - - 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_____] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0% 12 TYPE OF REPORTING PERSON* IA Page 2 of 5 PagesItem 1(a) Name of Issuer: Progenics Pharmaceuticals, Inc. Item 1(b) Address of Issuer's Principal Executing Offices: One World Trade Center, 47th Floor New York, NY 10007Item 2(a) Name of Person Filing: Eagle Asset Management, Inc. Item 2(b) Address of Principal Business Office: 880 Carillon Parkway St. Petersburg, Florida 33716 Item 2(c) Citizenship: Florida Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 743187106 Item 3 Type of Reporting Person: (e) Investment Adviser registered under Section 203 of the Investment Advisors Act of 1940 Page 3 of 5 PagesItem 4 Ownership as of 03/31/20 (a) Amount Beneficially Owned: 0 shares of common stock beneficially owned including: No. of Shares Eagle Asset Management, Inc. 0 (b) Percent of Class: 0 (c) Deemed Voting Power and Disposition Power: (i) (ii) (iii) (iv) Deemed Deemed Deemed Deemed to have to have to have to have Sole Power Shared Power Sole Power Shared Power to Dispose to Dispose to Vote or to Vote or or to or to to Direct to Direct Direct the Direct the to Vote to Vote Disposition Disposition Eagle Asset 0 ---- 0 ---- Management, Inc. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. (X) Item 6 Ownership of More than Five Percent on Behalf of Another Person: N/A Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company: N/A Page 4 of 5 PagesPage 5 of 5 Pages